الفلبين - الإنجليزية - FDA (Food And Drug Administration)

daily grace unlimited inc.; importer: n/a; distributor: n/a - ascorbic acid (as calcium ascorbate) , zinc (as zinc sulfate monohydrate) - capsule - 500 mg (equivalent to 605.2 mg calcium ascorbate)/ 20 mg (equivalent to 55 mg zinc sulfate monohydrate)

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

المملكة العربية السعودية - الإنجليزية - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen inc., united states - blinatumomab - powder for concentrate for solution for infusion - 35 µg

المملكة العربية السعودية - الإنجليزية - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen inc., united states - blinatumomab - powder for concentrate for solution for infusion - 35 µg

بنجلاديش - الإنجليزية - DGDA (Directorate General of Drug Administration)

united chemicals & pharmaceuticals ltd. - zinc - syrup - 10 mg/5 ml

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.2).,

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c, chronic - antivirals for systemic use - incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis c in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

h. lundbeck a/s - nalmefene hydrochloride dihydrate - alcohol-related disorders - drugs used in alcohol dependence - selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - mycophenolate mofetil 250mg;   - capsule - 250 mg - active: mycophenolate mofetil 250mg   excipient: croscarmellose sodium gelatin   hyprolose indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate   tekprint black sw-9008 titanium dioxide   water   - myaccord is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - mycophenolate mofetil 500mg;   - film coated tablet - 500 mg - active: mycophenolate mofetil 500mg   excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry purple 03b50110 povidone purified talc - for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.